Medical comms - Press Releases

Date	Title	Company
25-Mar-2022	TIACA Announces the Take-Off of the BlueSky Program	TIACA
25-Mar-2022	Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	Jazz Pharmaceuticals
25-Mar-2022	The last day for trading in Moberg Pharma's warrants of series 2020:1 is today, 25 March 2022	Moberg Pharma
25-Mar-2022	Envirotainer’s Releye® RAP container already approved by 10 airlines	Envirotainer
22-Mar-2022	New Phesi data highlights potential long-lasting impact from war in Ukraine on global clinical development	Phesi
22-Mar-2022	Innovative collaboration to offer heart rhythm checks throughout the North West to detect Atrial Fibrillation via Community Pharmacies	Daiichi Sankyo and O’Brien’s Pharmacies Group
22-Mar-2022	Zygel’s anticipated impact on underserved fragile X syndrome market sees sales estimates of $18.1 million, says GlobalData	Zynerba Pharmaceuticals
22-Mar-2022	Sajid Javid is sticking his head in the sand, expert warns, as long Covid cases mount and immunity falls	London Medical Laboratory
17-Mar-2022	Experienced director Godfrey Lisk joins AXON’s Medical practice	AXON
10-Mar-2022	konectar Social - connect with right DOLs	Aissel Technologies Inc
08-Mar-2022	Rapid Microbial Methods, Contamination Control, Sterility Assurance and Environmental Monitoring to be covered at Microbiology East Coast Conference in Boston	SMi Group
05-Mar-2022	Exclusive Chemaxon Interview released - Sponsor at AI in Drug Discovery Conference 2022	SMi Group
23-Feb-2022	New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks	Janssen
23-Feb-2022	Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone	Janssen
23-Feb-2022	The Majority of Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA®▼ (guselkumab)	Janssen
22-Feb-2022	Europe’s Only Parallel Trade Conference returns for its 16th Year	SMi Group
15-Feb-2022	Passive or Active? Supply chain leaders compare key pharmaceutical cold chain technologies in latest white paper	Tower Cold Chain
15-Feb-2022	Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer	The Janssen Pharmaceutical Companies of Johnson & Johnson
09-Feb-2022	Book to attend the Parallel Trade conference before seats are filled	SMi Group
03-Feb-2022	PENTAX Medical Europe launches premium solution PlasmaTYPHOON+	PENTAX Medical Europe